Allarity Therapeutics Stock Today
| ALLR Stock | USD 1.26 0.07 5.88% |
Performance0 of 100
| Odds Of DistressOver 81
|
Allarity Therapeutics is selling at 1.26 as of the 22nd of November 2024; that is 5.88 percent increase since the beginning of the trading day. The stock's lowest day price was 1.2. Allarity Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Allarity Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 23rd of October 2024 and ending today, the 22nd of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 21st of December 2021 | Category Healthcare | Classification Health Care |
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts. The company has 1.41 M outstanding shares of which 179.44 K shares are presently shorted by private and institutional investors with about 0.3 trading days to cover. More on Allarity Therapeutics
Moving together with Allarity Stock
| 0.91 | VRAX | Virax Biolabs Group | PairCorr |
| 0.7 | VRPX | Virpax Pharmaceuticals | PairCorr |
| 0.76 | DYN | Dyne Therapeutics | PairCorr |
| 0.7 | XFOR | X4 Pharmaceuticals | PairCorr |
Moving against Allarity Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Allarity Stock Highlights
| CEO, Founder | Thomas Jensen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Old Name | Allarity Therapeutics A/S | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsAllarity Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Allarity Therapeutics' financial leverage. It provides some insight into what part of Allarity Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Allarity Therapeutics (ALLR) is traded on NASDAQ Exchange in USA. It is located in 24 School Street, Boston, MA, United States, 02108 and employs 5 people. Allarity Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 2.06 M. Allarity Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 1.41 M outstanding shares of which 179.44 K shares are presently shorted by private and institutional investors with about 0.3 trading days to cover.
Allarity Therapeutics currently holds about 7.73 M in cash with (12.74 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.75.
Check Allarity Therapeutics Probability Of Bankruptcy
Ownership AllocationAllarity Therapeutics shows 12.3 percent of its outstanding shares held by insiders and 1.2 percent owned by other corporate entities.
Check Allarity Ownership Details
Allarity Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Virtu Financial Llc | 2024-06-30 | 265.3 K | |
| Geode Capital Management, Llc | 2024-06-30 | 102.3 K | |
| Ubs Group Ag | 2024-06-30 | 41.2 K | |
| Jump Financial Llc | 2024-06-30 | 38.8 K | |
| Hrt Financial Llc | 2024-06-30 | 34.7 K | |
| Jane Street Group Llc | 2024-06-30 | 15.7 K | |
| Tower Research Capital Llc | 2024-06-30 | 12.2 K | |
| Bank Of America Corp | 2024-06-30 | 145 | |
| Headlands Technologies Llc | 2024-09-30 | 0.0 | |
| Citadel Advisors Llc | 2024-06-30 | 0.0 |
Allarity Therapeutics Historical Income Statement
Allarity Stock Against Markets
Allarity Therapeutics Corporate Management
| Professor MD | CoFounder | Profile | |
| Joan Brown | Interim Reporting | Profile | |
| Alexander Epshinsky | Chief Officer | Profile | |
| James JD | Chief CEO | Profile | |
| Steen Knudsen | Founder Officer | Profile | |
| Annie Rasmussen | Chief Operations | Profile |
Already Invested in Allarity Therapeutics?
The danger of trading Allarity Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Allarity Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Allarity Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Allarity Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Allarity Stock Analysis
When running Allarity Therapeutics' price analysis, check to measure Allarity Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Allarity Therapeutics is operating at the current time. Most of Allarity Therapeutics' value examination focuses on studying past and present price action to predict the probability of Allarity Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Allarity Therapeutics' price. Additionally, you may evaluate how the addition of Allarity Therapeutics to your portfolios can decrease your overall portfolio volatility.